Prognostic role of pulmonary vein isolation in patients with atrial fibrillation and heart failure with preserved ejection fraction

Authors: Tarasova K.A., Berdibekov B.Sh., Bulaeva N.I., Golukhova E.Z.

Company: Bakoulev National Medical Research Center for Cardiovascular Surgery, Moscow, Russian Federation

For correspondence:  Sign in or register.

Type:  Reviews


DOI: https://doi.org/10.24022/1997-3187-2023-17-3-359-366

For citation: Tarasova K.A., Berdibekov B.Sh., Bulaeva N.I., Golukhova E.Z. Prognostic role of pulmonary vein isolation in patients with atrial fibrillation and heart failure with preserved ejection fraction. Creative Cardiology. 2023; 17 (3): 359–66 (in Russ.). DOI: 10.24022/1997-3187-2023-17-3-359-366

Received / Accepted:  21.08.2023 / 16.09.2023

Keywords: atrial fibrillation heart failure with preserved ejection fraction pulmonary vein isolation prognosis

Download
Full text:  

 

Abstract

Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are diseases, which worsen each other because of the common risk factors underlying both conditions. Pulmonary vein isolation (PVI) as method for AF treatment has shown its efficacy and safety. Studies have demonstrated the benefits of catheter ablation that could lead to decrease BNP levels, filling pressure of the left ventricle (LV) and to improve LV functional parameters in HFpEF. Moreover, there are evidence, which shows that PVI could decrease HFpEF burden and patients’ hospitalization and also death compared to pharmacological therapy AF. However nowadays there are no randomized clinical trials, investigating differences between pharmacological therapy AF and PVI. In this review we would like to discuss the role of catheter ablation in AF-HFpEF and the current evidence regarding its safety, efficacy and prognostic benefit.

References

  1. Lippi G., Sanchis-Gomar F., Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int. J. Stroke. 2021; 16 (2): 217–21. DOI: 10.1177/1747493019897870
  2. Ariyaratnam J.P., Lau D.H., Sanders P., Kalman J.M. Atrial fibrillation and heart failure: epidemiology, pathophysiology, prognosis, and management. Card. Electrophysiol. Clin. 2021; 13 (1): 47–62. DOI: 10.1016/j.ccep.2020.11.004
  3. Kotecha D., Lam C.S., Van Veldhuisen D.J., Van Gelder I.C., Voors A.A., Rienstra M. Heart failure with preserved ejection fraction and atrial fibrillation: vicious twins. J. Am. Coll. Cardiol. 2016; 68 (20): 2217–28. DOI: 10.1016/j.jacc.2016.08.048
  4. Gurwitz J.H., Magid D.J., Smith D.H., Goldberg R.J., McManus D.D., Allen L.A. et al. Contemporary prevalence and correlates of incident heart failure with preserved ejection fraction. Am. J. Med. 2013; 126 (5): 393–400. DOI: 10.1016/j.amjmed.2012.10.022
  5. Polyakov D.S., Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Artemeva E.G. et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of followup? Results of the EPOCH-CHF study. Kardiologiia. 2021; 61 (4): 4–14. DOI: 10.18087/cardio.2021.4.n1628
  6. Sugumar H., Nanayakkara S., Prabhu S., Voskoboinik A., Kaye D.M., Ling L.H. et al. Pathophysiology of atrial fibrillation and heart failure: dangerous interactions. Cardiol. Clin. 2019; 37 (2): 131–38. DOI: 10.1016/j.ccl.2019.01.002
  7. Arora S., Jaswaney R., Jani C., Zuzek Z., Thakkar S., Patel H.P. et al. Catheter ablation for atrial fibrillation in patients with concurrent heart failure. Am. J. Cardiol. 2020; 15 (137): 45–54. DOI: 10.1016/j.amjcard.2020.09.035
  8. Patel R.B., Vaduganathan M., Shah S.J., Butler J. Atrial fibrillation in heart failure with preserved ejection fraction: Insights into mechanisms and therapeutics. Pharmacol. Ther. 2017; 176: 32–9. DOI: 10.1016/j.pharmthera.2016.10.019
  9. Mollaeva D.D., Mashina T.V., Mrikaev D.V., Berdibekov B.Sh., Filatov A.G., Golukhova E.Z. Modern ultrasound techniques in the assessment of left atrium structural abnormalities in patients with atrial fibrillation. Creative Cardiology. 2021; 15 (2): 48–60. DOI: 10.24022/1997-3187-2021-15-1-48-60 (in Russ.).
  10. Borlaug B.A. Evaluation and management of heart failure with preserved ejection fraction. Nat. Rev. Cardiol. 2020; 17 (9): 559– 73. DOI: 10.1038/s41569-020-0363-2
  11. Ageev F.T., Yarovaya E.B., Ovchinnikov A.G. Рossibility of using European (HFA-PEFF) and American (H2FPEF) algorithms for diagnosing heart failure with preserved ejection fraction in Russian clinical practice. Kardiologiia. 2022; 62 (12): 4–10 (in Russ.). DOI: 10.18087/cardio.2022.12.n2280
  12. Reddy Y.N.V., Carter R.E., Obokata M., Redfield M.M., Borlaug B.A. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018; 138 (9): 861–70. DOI: 10.1161/CIRCULATIONAHA.118.034646
  13. Verbrugge F.H., Reddy Y.N.V., Sorimachi H., Omote K., Carter R.E., Borlaug B.A. Diagnostic scores predict morbidity and mortality in patients hospitalized for heart failure with preserved ejection fraction. Eur. J. Heart. Fail. 2021; 23 (6): 954–63. DOI: 10.1002/ejhf.2142
  14. Aldaas O.M., Malladi C.L., Mylavarapu P.S., Lupercio F., Darden D., Han F.T. et al. Comparison of outcomes after ablation of atrial fibrillation in patients with heart failure with preserved versus reduced ejection fraction. Am. J. Cardiol. 2020; 136: 62– 70. DOI: 10.1016/j.amjcard.2020.09.018
  15. Yamauchi R., Morishima I., Okumura K., Kanzaki Y., Morita Y., Takagi K. et al. Catheter ablation for non-paroxysmal atrial fibrillation accompanied by heart failure with preserved ejection fraction: feasibility and benefits in functions and B-type natriuretic peptide. Europace. 2021; 23 (8): 1252–61. DOI: 10.1093/europace/euaa420
  16. Elkaryoni A., Al Badarin F., Spertus J.A., Kennedy K.F., Wimmer A.P. Comparison of the effect of catheter ablation for atrial fibrillation on all-cause hospitalization in patients with versus without heart failure (from the Nationwide Readmission Database). Am. J. Cardiol. 2020; 125 (3): 392–8. DOI: 10.1016/j.amjcard.2019.10.048
  17. Rattka M., Pott A., Kühberger A., Weinmann K., Scharnbeck D., Stephan T., Dahme T. Restoration of sinus rhythm by pulmonary vein isolation improves heart failure with preserved ejection fraction in atrial fibrillation patients. EP Europace. 2020; 22 (9): 1328–36. DOI: 10.1093/europace/euaa101
  18. Allessie M., Ausma J., Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc. Res. 2002; 54 (2): 230–46. DOI: 10.1016/S0008-6363(02) 00258-4
  19. Fukui A., Tanino T., Yamaguchi T., Hirota K., Saito S., Okada N. et al. Catheter ablation of atrial fibrillation reduces heart failure rehospitalization in patients with heart failure with preserved ejection fraction. J. Cardiovasc. Electrophysiol. 2020; 31 (3): 682–8. DOI: 10.1111/jce.14369
  20. Packer D.L., Piccini J.P., Monahan K.H., Al-Khalidi H.R., Silverstein A.P., Noseworthy P.A. et al. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial. Circulation. 2021; 143 (14): 1377–90. DOI: 10.1161/CIRCULATIONAHA.120.050991

About Authors

  • Ksenia A. Tarasova, Postgraduate; ORCID
  • Bektur Sh. Berdibekov, Junior Researcher, Cardiologist; ORCID
  • Naida I. Bulaeva, Cand. Biol. Sci., Senior Researcher, Cardiologist, Head of Department, Head of Laboratory, Associate Professor of Chair; ORCID
  • Elena Z. Golukhova, Dr. Med. Sci., Professor, Academician of RAS, Director; ORCID

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery